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Apolipoprotein M mediates 
sphingosine-1-phosphate efflux 
from erythrocytes
Pernille M. Christensen1,2, Markus H. Bosteen1,2, Stefan Hajny1,2, Lars B. Nielsen1,3 & Christina 
Christoffersen1,2
Sphingosine-1-phosphate (S1P) is a bioactive lipid implicated in e.g. angiogenesis, lymphocyte 
trafficking, and endothelial barrier function. Erythrocytes are a main source of plasma S1P together 
with platelets and endothelial cells. Apolipoprotein M (apoM) in HDL carries 70% of plasma S1P, 
whereas 30% is carried by albumin. The current aim was to investigate the role of apoM in export of 
S1P from human erythrocytes. Erythrocytes exported S1P more efficiently to HDL than to albumin, 
particularly when apoM was present in HDL. In contrast, export of sphingosine to HDL was unaffected 
by the presence of apoM. The specific ability of apoM to promote export of S1P was independent of 
apoM being bound in HDL particles. Treatment with MK-571, an inhibitor of the ABCC1 transporter, 
effectively reduced export of S1P from human erythrocytes to apoM, whereas the export was 
unaffected by inhibitors of ABCB1 or ATPase. Thus, ABCC1 could be involved in export of S1P from 
erythrocytes to apoM.
Sphingosine-1-phosphate (S1P) is a small bioactive lipid and a ligand for five G-protein-coupled receptors 
(S1P1-S1P5) regulating multiple biological actions. For example, S1P promotes angiogenesis1,2, vascular matura-
tion during development, endothelial cell migration, endothelial barrier function3,4 and lymphocyte trafficking5. 
S1P is a metabolite from phosphorylation of sphingosine by sphingosine kinase 1 and 2 (Sphk1 and Sphk2)6,7. 
Bone-marrow derived cells, hepatocytes, endothelial cells, platelets, and erythrocytes express Sphk1 or Spkh2 and 
are potential contributors of plasma S1P2,5,8,9. It is of clinical importance to know the detailed regulation of plasma 
levels of S1P, since this will provide new targets for treatment of diseases affecting for example endothelial barrier 
function, lymphocyte trafficking, and angiogenesis.
A conditional knockout mouse with lack of both sphk1 and sphk25 and undetectable plasma S1P regain nor-
mal plasma S1P levels after bone marrow transplantation with cells from a WT mouse5. Hence, the bone marrow 
derived cells are able to produce and contribute to plasma S1P. Remarkably, however, transplantation of bone 
marrow from sphk1−/−sphk2+/− mice (with 65% reduced plasma S1P) into WT mice did not reduce plasma 
S1P9. This suggests that also non-hematopoietic cells, presumably endothelial cells, can maintain plasma S1P 
levels. Platelets secrete S1P upon thrombin stimulation2,10. Nevertheless, platelet-depleted mice display normal 
plasma S1P levels5,9. In humans, plasma levels of S1P correlate with the hematocrit11 and are decreased in patients 
with anemia12, suggesting that erythrocytes contribute to plasma S1P. In accordance with this observation, injec-
tion of WT erythrocytes into Sphk-deficient mice restores normal plasma levels of S1P5. Altogether, the current 
evidence suggests that multiple cell types can contribute to plasma S1P, but that erythrocytes likely account for the 
majority of the S1P production, at least in steady state.
Erythrocytes are unable to release S1P to a plasma- or serum-free medium. Hence, an acceptor needs 
to be present in order to promote S1P export13. In plasma, S1P is bound to albumin (~30%) or HDL parti-
cles (~70%)14,15, and both albumin and HDL can act as acceptors of S1P exported from erythrocytes12,16. The 
export of S1P from erythrocytes to albumin can be inhibited by glyburide (an inhibitor of the ATP-binding 
cassette transporter A1 (ABCA1))17, vanadate (a phosphate analogue and inhibitor of several ATPases)17, and 
1,4-dithioerythritol (an inhibitor of scramblase activity)12. In other cell types SPNS218 and ABCC119 can mediate 
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export of S1P, however they have not been established as transporters in erythrocytes. It is unknown whether S1P 
export to HDL involves ABC transporters and whether S1P is accepted by the lipid moiety of the HDL particles 
or specific HDL apolipoproteins.
HDL contains more than 40 different proteins. So far it has been shown that apoAI16, apoCI, or apoCII12 
cannot promote S1P export from erythrocytes. Recently, apoM was identified as the physiological carrier of S1P 
in plasma20. ApoM is a lipocalin and has a characteristic beta-barrel structure enclosing a hydrophobic bind-
ing pocket, which accommodates S1P20. ApoM is mainly associated with HDL particles (~5% of HDL particles 
contain an apoM molecule21). Thus, apoM-free HDL in humans does not contain any detectable S1P, and lack 
of apoM/S1P compromises the pulmonary endothelial barrier in mice, suggesting a unique biological role for 
apoM/S1P-containing HDL20. ApoM is expressed in the liver and kidney22, and apoM seems to play a significant 
role in S1P export from the liver23. However, erythrocytes are probably the main contributor of plasma S1P. It is 
unknown whether and how erythrocyte-produced S1P is transferred to apoM.
The purpose of this study was to explore to what extent apoM can serve as an acceptor of S1P from erythro-
cytes and to identify potential transporters involved in erythrocyte export of S1P to HDL.
Results
Isolation of HDL with and without apoM. In order to investigate the effects of apoM in human HDL on 
export of S1P from human erythrocytes, we developed an affinity column where monoclonal antibodies specific 
for human apoM were generated and coupled to a resin column. By passing purified human HDL over the col-
umn, we could isolate apoM-free human HDL-apoM from the flow-through and subsequently elute apoM-con-
taining human HDL + apoM from the column. Of note, the protein composition of HDL-apoM and HDL + apoM 
with regards to apoAI and apoAII, as analyzed with silverstained SDS-PAGE, was similar and human apoM was 
exclusively detected (by western blotting and ELISA) in HDL + apoM (see Supplemental Fig. S1). The molar ratio 
of S1P to apoM was found to be 1:5.5 for HDL + apoM. S1P was not detectable with a sensitive HPLC method in 
HDL-apoM.
HDL with and without apoM was isolated from human apoM transgenic (apoM-TgH) mice with 10-fold 
increase in human plasma apoM and apoM−/− mice without apoM24, respectively. The HDL particles contained 
similar levels of several apolipoproteins including apoAI and apoAII, as described previously25. Previous analysis 
showed that the molar ratio of S1P to apoM is ~1:6 for HDL from apoM-TgH mice and HDL from apoM−/− mice 
contains no detectable S1P20.
Export of S1P from erythrocytes to albumin and HDL. We first compared murine HDL with 
or without apoM and albumin as acceptors of S1P produced and secreted from human erythrocytes. 
3H-sphingosine-loaded erythrocytes were incubated with albumin, HDL from apoM-TgH mice or HDL from 
apoM−/− mice. At all protein concentrations tested (0.1–20 μg/ml total protein) more 3H-S1P was exported to 
HDL (1.75 ± 0.03% to 7.13 ± 0.73% for apoM-TgH HDL and 1.84 ± 0.09% to 4.31 ± 0.25% for apoM−/− HDL) 
than to albumin (1.62 ± 0.14% to 2.68 ± 0.11%) (Fig. 1a). The presence of human apoM in mouse HDL conferred 
a larger 3H-S1P export compared to HDL without apoM (7.13 ± 0.73% vs. 4.31 ± 0.25% at 20 μg/ml, p = 0.02) 
(Fig. 1a). The presence of apoM in human HDL also increased the ability of HDL to mediate export of 3H-S1P 
from erythrocytes (5.32 ± 0.22% vs. 4.05 ± 0.02%, at 10 µg/ml, p = 0.028) (Fig. 1c). Of note, even when the albu-
min concentration was increased to 500 µg/ml, HDL + apoM and HDL-apoM were still superior as mediators of 
3H-S1P export (Supplemental Fig. S2). Hence, a 10 times higher albumin concentration induces considerable less 
3H-S1P release as when compared to HDL.
In plasma, S1P is only found in HDL particles containing apoM20 and thus it was surprising that human and 
murine HDL without apoM could facilitate export of S1P from human erythrocytes. To assess if the effluxed 
3H-S1P was bound to HDL without apoM, supernatants from 3H-sphingosine-loaded human erythrocytes incu-
bated with human HDL with apoM or human HDL without apoM were subjected to gel filtration. As expected, 
when 3H-sphingosine-loaded erythrocytes had been incubated with HDL with apoM, 3H-S1P was mainly 
detected in the apoM-containing HDL particles (a smaller fraction was recovered as unbound 3H-S1P) (Fig. 2 
and Supplemental Fig. S3). Remarkably, however, when 3H-sphingosine-loaded erythrocytes had been incubated 
with HDL without apoM the 3H-S1P was almost exclusively detected in fractions corresponding to unbound S1P 
or in fractions with low concentration of apoA-I and albumin (Fig. 2 and Supplemental Fig. S3). Interestingly, if 
albumin was added afterwards to the supernatant from export assays using HDL-apoM as acceptor, 3H-S1P was 
recovered in fractions similar to experiments using albumin as acceptor (Fig. 3).
Since apoM-containing HDL from both mice and humans facilitated increased export of S1P from eryth-
rocytes as compared to apoM-free HDL, it was of interest to investigate whether apoM needed to be in com-
plex with HDL in order to promote S1P export. Hence, we assessed whether a truncated recombinant apoM 
protein (167 amino acids), lacking its HDL binding signal peptide (21 amino acids) but retaining its ability to 
bind S1P, could mediate S1P export from erythrocytes. Thus, 3H-sphingosine-loaded erythrocytes were incu-
bated with the recombinant apoM protein, albumin, haptoglobin, or immunoglobulins. At all concentrations 
tested (0.1–20 μg/ml) recombinant apoM protein was superior in promoting export of 3H-S1P compared to 
albumin (8.26 ± 1.21% vs. 2.14 ± 0.15%, at 20 µg/ml, p = 0.037) (Fig. 4a). Furthermore, in direct comparison 
with apoM-containing HDL from TgH mice, recombinant apoM protein promoted similar time-dependent 
(2–60 minutes) export of 3H-S1P from human erythrocytes (Fig. 5a). In a separate experiment, with prolonged 
incubation for up to 6 hours, recombinant apoM even lead to the highest amount of 3H-S1P exported after 
6 hours (28.80%) followed by apoM-TgH HDL (17.43%), apoMα HDL (11.50%), albumin (6.81%) and hapto-
globin (6.57%) (see Supplemental Fig. S4).
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Erythrocyte export of sphingosine. To determine whether apoM promoted a general export of sphingo-
lipids or whether the export was specific for S1P, we measured the export of 3H-sphingosine from human eryth-
rocytes. The erythrocytes exported considerably higher amounts of 3H-sphingosine when incubated with HDL 
compared to incubation with albumin (24.95 ± 2.08% vs. 1.15 ± 0.10% at 20 μg/ml, p = 0.0003), and the export 
Figure 1. ApoM-containing HDL increases export of S1P but not sphingosine from erythrocytes. Export of 
S1P (a and c) and export of sphingosine (b and d) from erythrocytes incubated 40 min with HDL from apoM 
transgenic mice (apoM-TgH), HDL from apoM−/− mice, and albumin (a and b) or human HDL + apoM, human 
HDL-apoM, and albumin (c and d). Results are expressed as % of the total cpm found in supernatants and 
pellets combined and plotted as mean ± SEM.
Figure 2. S1P is only bound to HDL particles containing apoM. Measurement of 3H-S1P in gel filtration 
fractions from export assays with human HDL + apoM (_______) or HDL-apoM (- - - - -) as acceptors (10 µg/ml). 
Radioactivity in the selected fractions is shown as cpm after correction for background activity. The results shown 
are representative of two separate experiments. The black bar indicates fractions where HDL particles are eluted.
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Figure 3. S1P exported to HDL-apoM can associate with albumin. Measurement of 3H-S1P in gel filtration 
fractions from export assays with 500 µg/ml albumin (______) or 10 µg/ml human HDL-apoM (- - - - -) as 
acceptors. After export, supernatants from assays with HDL-apoM were mixed with 500 µg/ml albumin and 
allowed to incubate for 10 minutes at 37 °C before subjected to gel filtration. Radioactivity in the selected 
fractions is shown as cpm after correction for background activity. The black bar indicates fractions where HDL 
particles are eluted.
Figure 4. Export of S1P from erythrocytes requires presence of physiological carrier proteins. Export of S1P (a) 
and export of sphingosine (b) from erythrocytes incubated 40 min with recombinant apoM protein, albumin, 
haptoglobin, or immunoglobulins. Results are expressed as % of the total cpm in supernatants and pellets 
combined and plotted as mean ± SEM.
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of 3H-sphingosine to HDL was not affected by apoM (Fig. 1b,d). Recombinant apoM protein was slightly more 
effective in promoting export of 3H-sphingosine (1.69 ± 0.02% at 20 μg/ml) compared to albumin (0.95 ± 0.16% 
at 20 μg/ml), haptoglobin (0.52 ± 0.05% at 20 μg/ml) or immunoglobulins (0.63 ± 0.15% at 20 μg/ml) (Fig. 4b). 
However, when compared to HDL particles, all of the tested proteins were markedly less efficient in promoting 
3H-sphingosine export (compare Figs 1b and 5b).
S1P export from erythrocytes is inhibited by MK-571, an ABCC1 inhibitor. To investigate trans-
porter pathways involved in S1P export from erythrocytes to apoM, several inhibitors of ABC transporters 
were screened for their effect on 3H-S1P export to recombinant apoM protein. Probenecid (inhibitor of several 
ABCC transporters), Verapamil (inhibitor of ABCB1), and Vanadate (ATPase inhibitor) all had limited inhib-
itory effect on 3H-S1P export (maximum inhibition 29%, 37%, and 20%, respectively) at the concentrations 
tested (0.01–1 mM) (Fig. 6a). In contrast, the ABCC1 inhibitor MK-571 effectively reduced 3H-S1P export to the 
medium by 88% (50 μM) in the initial screening. Further experiments showed that MK-571 reduced the export of 
3H-S1P from erythrocytes in a concentration-dependent manner (0.01–100 μM) (Fig. 6b).
S1P export is not altered in erythrocytes from Abcc1-deficient mice. To further investigate the 
role of ABCC1 in export of S1P from erythrocytes, we isolated erythrocytes from Abcc1-deficient mice and their 
wildtype controls. When the Abcc1-deficient erythrocytes were used in the S1P export assay, we observed no 
difference in S1P export to recombinant apoM protein compared to erythrocytes from wildtype controls (Fig. 7).
Discussion
The present data suggest that HDL promotes export of S1P from human erythrocytes compared to albumin and 
that this is further enhanced when apoM is present in the HDL particles. Furthermore, we find that apoM can 
effectively promote export of S1P independently of its association with HDL, i.e. as free recombinant protein, and 
that the ABCC1 transporter could be involved in export of S1P from human erythrocytes to apoM. Finally, we 
show that export of sphingosine from erythrocytes is unaffected by the presence of apoM in HDL.
We have identified that apoM-containing HDL increases the export of S1P from human erythrocytes com-
pared to apoM-free HDL and albumin. These observations are supported by a recent study by Sutter et al.16, 
Figure 5. ApoM facilitates increased S1P export over time. Export of S1P (a) and sphingosine (b) from erythrocytes 
incubated with HDL from apoM transgenic mice (ApoM-TgH), HDL from apoM−/− mice, recombinant apoM 
protein, albumin, haptoglobin, or assay buffer without any protein. Total protein concentration 20 µg/ml and samples 
were incubated 2 to 60 minutes. Results are expressed as % of the total cpm in supernatants and pellets combined and 
plotted as mean ± SEM.
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Figure 6. S1P export from erythrocytes is inhibited by an ABCC1 inhibitor MK-571. Export of S1P 
from erythrocytes incubated with recombinant apoM protein (20 µg/ml) in (A) the initial screening of 
various concentrations of Probenecid, Verapamil, Vanadate, and MK-571 and (B) screening of additional 
concentrations of MK-571. In (A) concentrations of MK-571 above 0.1 mM led to hemolysis and were excluded. 
Results are expressed as % of the export seen from erythrocytes incubated without inhibitor. In (B) the results 
are plotted as mean ± SEM.
Figure 7. S1P export from ABCC1-deficient murine erythrocytes is unaltered. Export of S1P from erythrocytes 
isolated from Abcc1−/− or Wt mice after incubation for 40 min with recombinant apoM (0–50 µg/ml). Results 
are expressed as % of the total cpm measured in supernatants and pellets combined. The experiment was 
repeated twice and data are plotted as mean ± SEM.
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despite the use of two different experimental setups. They showed that incubation of erythrocytes with HDL 
from apoM transgenic mice increased accumulation of S1P in the medium compared to incubation with HDL 
from WT or apoM−/− mice or incubation with albumin. Sutter et al.16 incubated erythrocytes with the various 
acceptors and measured total S1P content in the medium whereas the present study used erythrocytes preloaded 
with 3H-labelled sphingosine and subsequent measured 3H-sphingosine and 3H-S1P in the medium and cells. 
With this experimental setup we found that HDL with apoM isolated from both human and mouse plasma 
increased the export of 3H-S1P from human erythrocytes compared to HDL without apoM. The difference 
between HDL with apoM and HDL without apoM seemed to be more pronounced for murine HDL than human 
HDL. This could be not explained by the S1P to apoM ratio, which was similar for murine TgH HDL and human 
HDL + apoM.
In plasma, HDL-S1P is only detectable in the apoM containing fraction20. Therefore, it was somewhat sur-
prising that even HDL without apoM mediated 3H-S1P export from human erythrocytes, albeit less effective 
than HDL with apoM. Notably, this observation was not due to cross contamination of 3H-sphingosine since the 
currently employed separation of 3H-S1P and 3H-sphingosine was almost complete with 99% recovery of 3H-S1P, 
as described in the methods section. Moreover, the notion that HDL without apoM is capable of inducing export 
of S1P from erythrocytes is in agreement with the S1P mass measurement by Sutter et al.16. The present study 
suggests that even though S1P is efficiently exported in presence of HDL without apoM, it is not bound to the 
HDL particles when apoM is not present. This is in line with in vivo observations, where S1P is undetectable in 
apoM-free HDL20. It is possible that S1P associates weakly with apoM-free HDL, probably by binding to the lipid 
moiety, during the export process and subsequently is transferred to either apoM-containing HDL or albumin in 
vivo. Our data support that S1P exported to HDL without apoM can be transported to albumin if present in suf-
ficient amounts. Furthermore, since HDL with or without apoM both are able to induce S1P export from eryth-
rocytes to a significantly larger extend than albumin, other apolipoproteins than apoM could serve as co-factors 
driving the export process. The identity of such co-factor still remains to be determined.
The biological roles of S1P are multiple. S1P regulates angiogenesis, migration of endothelial cells, vascular 
development, and enhancement of the endothelial barrier among others. Hence, to understand the metabolism 
of S1P it is important to including possible regulated transport mechanisms. Therefore, efforts have been made 
to identify the transporter(s) responsible for exporting S1P from erythrocytes. Transport of S1P in inside-out 
vesicles from rat erythrocytes is ATP-dependent and inhibited by Glyburide, an ABCA1 inhibitor17. However, 
ABCA1 expression was undetectable in the inside-out vesicles and thus excluded as the responsible S1P trans-
porter17. Further, Vanadate, a phosphate analogue that inhibits several ATPases, also inhibited release of S1P17. 
These observations were however challenged by a second study which showed no decrease in S1P export from 
human erythrocytes after treatment with Vanadate12. Instead a scramblase inhibitor effectively reduced the export 
of S1P from erythrocytes12. We propose that the ABCC1 transporter is involved in the export of S1P, since treat-
ment with MK-571 (an ABCC1 inhibitor) significantly inhibits release of S1P from human erythrocytes to recom-
binant apoM protein. The ABCC1 transporter could be a candidate, supported by the observation that ABCC1 
also is responsible for export of S1P in mast cells19. However, MK-571 had no effect on S1P release from intact 
rat erythrocytes nor from inside-out vesicles17. Reasons for the deviations could be that Kobayashi et al. used 
rat erythrocytes and albumin, whereas we have used human erythrocytes and recombinant apoM protein as an 
S1P acceptor. In our hands, albumin as acceptor release substantially lower amounts of S1P from erythrocytes 
compared to recombinant apoM protein or HDL. Thus, the effects of MK-571 could be blurred when using 
albumin as an acceptor since secretion of S1P to albumin is minimal already without use of inhibitor. Also, it 
cannot be excluded that different export mechanisms exist for export to albumin and apoM or for export in 
rat and human erythrocytes. It is already known that there is functional diversity between S1P-albumin and 
S1P-apoM-containing HDL. For example, to initiate tight junction formation via S1P1 the S1P-apoM complex is 
needed, whereas the S1P-albumin complex in vitro and in vivo is not able to induce similar levels of S1P1 mediated 
tight junctions causing increased vascular permeability20.
In our initial screening Probenecid only led to limited inhibition of S1P export. Probenecid is an inhibitor 
targeting multiple ABCC transporters; hence an inhibitory effect comparable to the effect seen with MK-571 
would be expected. It is possible that the concentrations used of Probenecid were insufficient to get maximal 
inhibition, that the incubation time was too short or that the affinity of Probenecid to ABCC1 was lower than 
to the other ABCC transporters. Additionally, we analyzed ABCC1 inhibition with Cediranib, a VEGF receptor 
tyrosine kinase inhibitor, described in one study to have inhibitory effects on ABCC1 in human carcinoma cell 
lines26. However, the results showed no inhibition of S1P export from human erythrocytes (data not shown), indi-
cating thatABCC1 is not responsible for S1P transport in human erythrocytes or that Cediranib is not effective as 
ABCC1 inhibitor in our experimental setup.
Surprisingly, erythrocytes from ABCC1-deficient mice retained the ability to export S1P in the presence of 
apoM. This suggests that the ABCC1 transporter is not essential for export of S1P from murine erythrocytes. In 
human erythrocytes, our results with MK-571 indicate that ABCC1 may play an essential role in S1P release. 
MK-571 is, however, also a leukotriene D4 antagonist27 and thus could potentially interfere with the general lipid 
signaling in the erythrocytes, thereby affecting the export of S1P. To further elucidate the role of ABCC1 in export 
of S1P, development of specific ABCC1 inhibitors are needed. Taken together, more experiments are needed to 
definitively determine both the significance of human ABCC1 in S1P export, and the species specific role of of 
apoM.
Clinically, a further development of MK-571, Montelukast, is used in prophylactic treatment of patients with 
asthma. Based on our observations that MK-571 inhibits the secretion of S1P from human erythrocytes, it could 
be interesting to determine if plasma levels of S1P in these patients are altered. Further, even though we only 
observed a modest effect of Verapamil and Probenecid on S1P export, these compounds are used clinically in 
treatment of arrhythmias and gout, respectively. Thus, determination of plasma S1P levels in these patient groups 
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could also be of interest. To our knowledge, this has yet to be done. S1P is a potent bioactive lipid, involved in 
angiogenesis, endothelial barrier function, and lymphocyte migration among others. Hence, to be able to target 
treatment for control of plasma S1P levels will be of great clinical value.
In conclusion we show that HDL promotes increased export of S1P from human erythrocytes and that this is 
further enhanced by the presence of apoM. Also, apoM induces S1P export from erythrocytes independently of 
binding to HDL particles. Our observations are supported by previous findings from Sutter et al.16 despite two 
different experimental setups. Finally, we propose that the ABCC1 transporter could be involved in export of S1P 
from human erythrocytes and that analysis of plasma S1P from patients treated with inhibitors of ABCC1 could 
be of clinical interest.
Materials and Methods
Measurement of S1P. Concentration of S1P in bovine serum albumin, HDL + apoM or HDL-apoM was 
performed as previously described20.
S1P export from erythrocytes. The protocol was modified from Kobayashi et al.17. Fresh blood samples 
from healthy human volunteers were drawn in K3EDTA vials and centrifuged 10 min at 3,000 rpm at RT. Plasma 
and buffycoat was discarded and erythrocytes were pooled. Pooled erythrocytes (2.5 μl) were mixed with 1 ml 
Buffer A (20 mM HEPES, 3.3 mM NaH2PO4, 2.9 mM KCl, 1 mM MgCl2, 138 mM NaCl, 1 mg/ml glucose, pH 
7.4) for 5 min at 37 °C and 500 rpm. 3H-sphingosine (20 pmol, specific activity 20 Ci/mmol) was added to the 
erythrocytes and incubated 5 min at 37 °C and 500 rpm. After incubation, the erythrocytes were centrifuged 5 sec-
onds at 12,000 g and RT, and the pellet was washed twice with 200 μl Buffer A and resuspended in 10 μl Buffer 
A. The resuspended erythrocytes (2 μl) were added to tubes containing 200 μl acceptor diluted in Buffer A (total 
protein concentration 0.1–20 μg/ml) and incubated at 500 rpm and 37 °C for 40 min unless otherwise indicated. 
Total protein concentration of each acceptor was determined with Pierce BCA Protein Assay Kit (23225, Thermo 
Scientific). Finally, the erythrocytes were pelleted at 12,000 g for 5 seconds and the supernatants were transferred 
to new tubes for extraction. The pellets were washed twice with 200 μl Buffer A and resuspended in 25 μl ethanol 
for extraction.
Extraction and quantification of 3H-sphingosine and 3H-S1P. Aliquots of the supernatants (150 μl) 
and the pellets were mixed with 150 μl chloroform:methanol (1:2 v/v) and sonicated in a water bath for 5 min 
followed by 2 min vortex. Then, 1 M NaCl (100 µl), 3 M NaOH (10 µl) and chloroform (100 µl) was added followed 
by 5 min vortex and 2 min centrifugation at 13,000 g and RT. This separates S1P into the upper aqueous phase and 
sphingosine into the lower organic phase. The aqueous phase was transferred to clean tubes and the organic phase 
was re-extracted with chloroform:methanol as above. The two aqueous phases combined (approximately 600 μl) 
and the organic phase (approximately 400 μl) were added to 10 ml OptiPhase (Perkin Elmer) and counted in a 
liquid scintillation counter. The amount of radioactivity in each sample was expressed as % of the total cpm in the 
aqueous and organic phases from supernatant and pellet combined.
The efficacy of the extraction protocol was tested by extraction of samples with fixed amounts of 3H-labelled 
sphingosine and S1P, respectively. The recovery of S1P in the aqueous phase was 99% and the recovery of sphin-
gosine in the organic phase was 92%. Subsequently, to decrease the amount of radioactivity in the aqueous phase 
resulting from impurities, 3H-sphingosine was ‘purified’ by extraction and isolation of the organic phase, which 
was then evaporated and re-dissolved in ethanol. The ‘purified’ 3H-sphingosine was used in all experiments.
Gel filtration. Supernatants from three individual S1P export assays (acceptor concentration 10 µg/ml of 
HDL-apoM and HDL + apoM or 500 µg/ml albumin) were pooled, mixed with 100 µl PBS + 0.1 g/l EDTA (700 µl 
total) and sterile filtered through a 0.45 µm filter. The pool (500 µl) was injected into a Superose 6 10/300 GL col-
umn (17-5172-01, Pharmacia Biotech) and run with PBS + 0.1 g/l EDTA at a flow of 0.3 ml/min. Fractions of six 
droplets were collected in a 96-well plate and selected fractions corresponding to a range of HDL particle sizes as 
well as unbound S1P were extracted with chloroform:methanol and quantified for 3H-S1P as described above. A 
second experiment was performed using 10 µg/ml HDL-apoM as acceptor as described above. After isolation of 
supernatants and prior to gelfiltration, the supernatants were incubated for 10 minutes at 37 °C in the presence of 
500 µg/ml albumin.
To verify protein content, subsets of gel-filtration fractions (60 µl) were subject to trichloracidic precipitation 
prior to 12% SDS-PAGE and silver staining analysis.
ABC-transporter inhibition assays. The S1P export assay was performed as described above with the addi-
tion of 5 min incubation at 37 °C with the inhibitors (concentration range 0.01–1 mM) prior to addition of acceptor. 
Probenecid and MK-571 was dissolved in buffer A, Vanadate was dissolved in H2O adjusted to pH 10 with NaOH, 
and Verapamil was dissolved in ethanol. The amount of solvent was below 1.5% of the total reaction volume.
Production of recombinant apoM protein. Human apoM protein without the signal peptide (amino 
acids 1–21) and with an 8.5 kDa N-terminal Profinity eXactTM tag was cloned and expressed in CHO cells by 
Evitria AG (Schlieren, Switzerland). Recombinant apoM protein was purified from cell supernatants by Profinity 
eXactTM purification system (BioRad) according to the manufacturer’s protocol. The purified recombinant apoM 
was assessed by coomassie-stained SDS-PAGE, and western blot. Folding and biological activity of the recombi-
nant protein was tested by the ability of S1P and palmitic acid to bind and quench the intrinsic tryptophan fluo-
rescence of apoM as described20,28. S1P and palmitic acid was dissolved in chloroform/methanol/dimethyl-amine 
(40 wt. % in H2O) in a 5:15:3 ratio to a stock concentration of 2.6 mM. Purified recombinant apoM protein spe-
cifically binds S1P (see Supplemental Fig. S5).
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Purification of HDL with and without apoM. Mouse and human HDL (1.063 < d < 1.21) was isolated by 
sequential fixed density ultracentrifugation of plasma from ApoM-TgH 24, ApoM−/− mice24, and healthy human 
donors. Ultracentrifugation was performed at 50,000 rpm and 4 °C for 16 hours (d = 1.063) or 24 hours (d = 1.21) 
in a Beckman Optima LE-80K ultracentrifuge with a Ti 50.4 rotor (Beckman Coulter). Density was adjusted with 
NaBr solutions containing 0.1 g/l EDTA and isolated lipoprotein fractions were dialyzed against PBS with 0.1 g/l 
EDTA. Total protein concentration in the isolated fractions was determined with Pierce BCA Protein Assay Kit 
(23225, Thermo Scientific).
Antibodies against human apoM were generated in mice by six sequential immunizations (interval of 2 weeks) 
with 100 µg recombinant apoM protein in incomplete Freund’s adjuvant. The mouse recipient obtaining highest 
antiserum reactivity (tested by indirect ELISA screening using purified HDL from apoM-TgH mice as antigen) 
was selected and boosted by a single injection before extraction and fusion of splenocytes. Indirect ELISA of cell 
supernatants with purified HDL from apoM-TgH mice as antigen identified 29 positive hybridoma clones. One 
specific antibody clone(19–01) was chosen and Protein-G purified antibodies from the cell culture supernatant 
were used for generation of an affinity column for human apoM. The antibody was immobilized by coupling to 
1 ml HiTrap NHS-activated agarose resin (17-0716-01, GE Healthcare). Purified HDL (10 ml, ~42 mg total pro-
tein) from human plasma was passed over the antibody-coupled resin column. ApoM-containing HDL particles 
were subsequently eluted from the column by 0.1 M glycine, pH 2.2. The column was washed with 5 ml H2O fol-
lowed by 5 ml tris-buffered saline. The procedure was repeated until apoM was undetectable in the flow-through 
(three times in total). Total protein concentration in the eluate and flow-through was determined by Pierce BCA 
Protein Assay Kit (23225, Thermo Scientific). The HDL + apoM and HDL-apoM particles were assessed with 
silver staining of SDS-gels, western blot against human apoM and ELISA measurement of human apoM29. The 
absence of S1P in HDL-apoM particles was confirmed with HPLC analysis20.
Mice. Abcc1−/− (FVB.129P2-Abcc1atm1Bor N12) mice and their wildtype controls (FVB.129) were pur-
chased from Taconic and blood samples were collected from the tail vein. The mice were housed in a 
temperature-controlled facility with a 12-hour light/dark cycle at the Panum Institute, University of Copenhagen 
with water and chow diet ad libitum. All experiments were approved by The Animal Experiments Inspectorate, 
Ministry of Environment and Food of Denmark, and performed in accordance with appropriate guidelines and 
regulations from the The Animal Experiments Inspectorate.
Ethics. All blood samples were collected from informed healthy volunteers. The samples were anonymized 
and materials were pooled from all individuals before further analysis. This was done in agreement with guide-
lines from the Regional Committees on Health Research Ethics for Region Hovedstaden, Denmark.
Statistics. Statistical analyses were performed with GraphPad Prism version 4.03 (GraphPad Software, Inc.). 
Student’s t-test was used to compare data points obtained with different acceptor molecules at similar concen-
trations. P-values ≤ 0.05 were considered statistically significant. All experiments were conducted in duplicate or 
triplicate and data are presented as mean ± SEM.
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